Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NUHUOYpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vvbmlEPTB;NT64OlY3KM7:TR?= MmrqV2FPT0WU
DOHH-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvjVG5XUUN3ME25MlM2Pjh7IN88US=> NVv3SYpDW0GQR1XS
no-10 Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q4S2lEPTB;OT65NFM6KM7:TR?= M2nIUnNCVkeHUh?=
LS-513 M3\1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTrOIFKSzVyPUGxMlM2PDdizszN NHPtOHpUSU6JRWK=
ALL-PO NF\U[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvrTGFKSzVyPUGxMlc4OzRizszN M4LHbnNCVkeHUh?=
8-MG-BA NVn0dXJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfJTWM2OD1zMz6xNVI{KM7:TR?= MXTTRW5ITVJ?
RPMI-8402 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGKxcYdKSzVyPUG1Mlg2OzdizszN M33jXnNCVkeHUh?=
EoL-1-cell NFu3dFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i0OWlEPTB;MUiuOVk1QCEQvF2= NVjRUYp5W0GQR1XS
NALM-6 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zxV2lEPTB;MUmuNFE3PyEQvF2= NVS2V3M4W0GQR1XS
DEL NGix[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jzNGlEPTB;MkCuNVQ4OSEQvF2= MV\TRW5ITVJ?
SR NHHrd|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnryTWM2OD1{Mz62O|E2KM7:TR?= M33WcnNCVkeHUh?=
697 NW[3WmJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXuZmx7UUN3ME2yOk43OTV3IN88US=> MW\TRW5ITVJ?
COLO-829 NXzxcGtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPyTWM2OD1{Nj64OFg{KM7:TR?= M2XYSnNCVkeHUh?=
EVSA-T M173bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XydmlEPTB;MkeuOVU3OSEQvF2= MmLPV2FPT0WU
ATN-1 M4jVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TZc2lEPTB;M{GuNlMzQSEQvF2= M2nYfnNCVkeHUh?=
L-363 Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvXTWM2OD1|MT63OFYyKM7:TR?= M1S5fHNCVkeHUh?=
LAMA-84 Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTN{LkWyNVEh|ryP MV;TRW5ITVJ?
NOS-1 MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTN2LkK5OVYh|ryP NVnBSWFHW0GQR1XS
BB30-HNC NYqxWo1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfYV3JoUUN3ME2zOE4{OzB4IN88US=> NFXzbG9USU6JRWK=
BC-1 M3v2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe3WZlKSzVyPUO3Mlk4PDZizszN NHfxVm1USU6JRWK=
IST-SL2 M3fNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1q0RmlEPTB;M{iuNlI1KM7:TR?= MkHIV2FPT0WU
D-392MG MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELyV4JKSzVyPUSwMlIzOTVizszN NV\BcI5DW0GQR1XS
no-11 NUTSXm5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[4TVRKSzVyPUSwMlU2OjFizszN NEj2fopUSU6JRWK=
LC4-1 MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXBfHVKSzVyPUSwMlg4OTZizszN NGrrUZBUSU6JRWK=
A388 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUG4UIp2UUN3ME20Nk42QDR6IN88US=> MW\TRW5ITVJ?
NTERA-S-cl-D1 NVnpboZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzYc45SUUN3ME20Nk44ODd2IN88US=> MmPoV2FPT0WU
CESS NU\lTJJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\2TWM2OD12ND6yNlMzKM7:TR?= NFr0NmVUSU6JRWK=
RS4-11 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjJWodKSzVyPUS5MlA6OzhizszN MXfTRW5ITVJ?
MS-1 NFX3V4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjSUFRKSzVyPUWwMlk{PTFizszN M4DVOnNCVkeHUh?=
CTV-1 NWe2d5BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rX[2lEPTB;NUGuNFc1KM7:TR?= NH3P[WhUSU6JRWK=
D-502MG MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrRTWM2OD13MT62NlcyKM7:TR?= MlHKV2FPT0WU
ML-2 M4HaNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTV{LkmxPVUh|ryP NIPtXmZUSU6JRWK=
SK-NEP-1 NGfHXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDrTZRPUUN3ME21N{4{QTJ|IN88US=> NUnoPIZ6W0GQR1XS
LOXIMVI NVnwPVNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\UWmlEPTB;NUOuOVg5PCEQvF2= NUXjV5NUW0GQR1XS
DJM-1 NFj5XpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnvTWM2OD13Nj6zN|kyKM7:TR?= MXTTRW5ITVJ?
GI-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXh[pJKSzVyPUW2MlYyPDlizszN MojJV2FPT0WU
IST-MES1 NWX6bI43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TDSGlEPTB;NkCuOVQ6OyEQvF2= M3;zW3NCVkeHUh?=
MV-4-11 NXTud5JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTZyLk[1N|gh|ryP Moq4V2FPT0WU
OVCAR-4 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLNTWM2OD14Mz61OlU4KM7:TR?= Mme3V2FPT0WU
KE-37 NIHVNm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTZ4LkK2Olgh|ryP NUDobGV1W0GQR1XS
D-542MG NIjkTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3LVmVKSzVyPU[4MlQyOzVizszN MkLOV2FPT0WU
MHH-PREB-1 NIXWcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPIPGo2UUN3ME23Nk45PDRzIN88US=> MYXTRW5ITVJ?
MRK-nu-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P6UWlEPTB;N{OuOFcxPSEQvF2= NFzBeVJUSU6JRWK=
D-247MG NV22XYFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH4dVdiUUN3ME23N{42PDR{IN88US=> M17NZXNCVkeHUh?=
OCI-AML2 MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkSzTWM2OD15Nj65N|Y6KM7:TR?= NWC2RlhwW0GQR1XS
LP-1 MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrQTWM2OD16Mj64O|MyKM7:TR?= MWfTRW5ITVJ?
HCC1599 NUP3T|lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL0TWM2OD16ND6yPFM4KM7:TR?= M2r4[XNCVkeHUh?=
KARPAS-45 MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTh2Lk[5PVIh|ryP MoiwV2FPT0WU
BE-13 NUjPfFR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjsXYxKSzVyPUm5MlA1PzdizszN Mn;EV2FPT0WU
GCIY M3\UbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYmwXHI1UUN3ME25PU4xQTV2IN88US=> MnT5V2FPT0WU
BV-173 NF\MT29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nnUmlEPTB;MUCwMlMzPSEQvF2= NFPnWVNUSU6JRWK=
LB2518-MEL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrQWYhKSzVyPUGwNE44QDlizszN M2fBV3NCVkeHUh?=
KS-1 M{fRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3OWlZmUUN3ME2xNFEvPjN7IN88US=> MYHTRW5ITVJ?
MOLT-16 MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonuTWM2OD1zMESuPVg3KM7:TR?= NFniNHhUSU6JRWK=
NCI-H1770 NI\lZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHKzUpZKSzVyPUGwPE44QDRizszN MnLLV2FPT0WU
NCI-H82 NV;tZY1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFzMD65O|Yh|ryP NGf1RY5USU6JRWK=
NCCIT MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHEWVNYUUN3ME2xNVIvPTJ7IN88US=> NED1PGNUSU6JRWK=
KALS-1 NGH5eZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHNNnRnUUN3ME2xNVUvQTRzIN88US=> M3K2SXNCVkeHUh?=
LB2241-RCC MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHi[5R7UUN3ME2xNVYvPjd7IN88US=> NWDhT4lPW0GQR1XS
HH NUXxeXJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDNTWM2OD1zMUeuN|k2KM7:TR?= M3rvUXNCVkeHUh?=
HD-MY-Z MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfQTWM2OD1zMUiuOFg5KM7:TR?= MWfTRW5ITVJ?
EB-3 NH7TNZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnkdHRKSzVyPUGyN{4xQTRizszN NHnwNYxUSU6JRWK=
BL-70 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLOOW1nUUN3ME2xNlMvOTJ5IN88US=> M{TxUnNCVkeHUh?=
K-562 MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C5bWlEPTB;MUK2MlI1PSEQvF2= NWrmbm1oW0GQR1XS
HT-144 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF|Mz6xOlQh|ryP M4LpSXNCVkeHUh?=
PF-382 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF|ND6zOlEh|ryP MoS5V2FPT0WU
RPMI-8226 NE\DOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LySWlEPTB;MUO1MlA1PSEQvF2= MXLTRW5ITVJ?
NCI-H1355 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfn[JlKSzVyPUGzOU42QDdizszN MnzQV2FPT0WU
LXF-289 MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLETWM2OD1zM{muO|gyKM7:TR?= MXzTRW5ITVJ?
NCI-H69 M3\MZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf6TWM2OD1zNEKuPVMzKM7:TR?= M2W4SXNCVkeHUh?=
SK-MEL-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF2Nz6xN{DPxE1? MoLQV2FPT0WU
KARPAS-299 NV\2VlVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jNfmlEPTB;MUS5MlEzKM7:TR?= MVnTRW5ITVJ?
GB-1 NWHXbJQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rDRWlEPTB;MUS5MlMzOiEQvF2= MV7TRW5ITVJ?
CMK M{\J[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF2OT61NVUh|ryP M4DDRXNCVkeHUh?=
MPP-89 NEK4O21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnQZ2J[UUN3ME2xOVYvODN3IN88US=> NHfHU3lUSU6JRWK=
KU812 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITWN49KSzVyPUG2NU46ODJizszN NHTUfZBUSU6JRWK=
REH MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHy[nhSUUN3ME2xOlIvOTJ3IN88US=> NX\Bb|hmW0GQR1XS
NEC8 NHnSUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF4NT6wNlYh|ryP M1LXXHNCVkeHUh?=
KP-N-YS NV3JUnN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF4OD6zPVUh|ryP NWTnNnBzW0GQR1XS
Ramos-2G6-4C10 NXLWR|ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF4OT65NVUh|ryP NYDXcnllW0GQR1XS
Becker NVH3XlNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF5ND6xPEDPxE1? M1HyfHNCVkeHUh?=
LB647-SCLC Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DHbGlEPTB;MUe1Mlg1PSEQvF2= Ml:xV2FPT0WU
LU-139 M1fjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LnZmlEPTB;MUe4MlAyQSEQvF2= NETsTpNUSU6JRWK=
QIMR-WIL NIHFVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;6T2lEPTB;MUe5MlY1PiEQvF2= MlvxV2FPT0WU
NCI-H1395 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX0PIFxUUN3ME2xO|kvQTl4IN88US=> MonCV2FPT0WU
NOMO-1 MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzMTWM2OD1zOEKuPFUh|ryP M{DPRXNCVkeHUh?=
GI-ME-N MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf3TWM2OD1zOEeuPVY6KM7:TR?= MYXTRW5ITVJ?
KMS-12-PE NYHJPVdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXCbVFJUUN3ME2xPFkvOjd|IN88US=> NH\1WGRUSU6JRWK=
Daudi NXrBNoRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\kTWM2OD1zOUGuNVI5KM7:TR?= M{LFWnNCVkeHUh?=
LB996-RCC NIm5R3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jQSGlEPTB;MUmxMlY6QSEQvF2= MWnTRW5ITVJ?
NCI-H2107 M3HaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnKwTWM2OD1zOUOuO|M6KM7:TR?= NEHkdVlUSU6JRWK=
SK-PN-DW NVzUdXgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX1TWM2OD1zOUSuO|E6KM7:TR?= MlfVV2FPT0WU
MC-CAR NYe2emV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJyMj6yOVMh|ryP M4SzWHNCVkeHUh?=
SNB75 MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ThfmlEPTB;MkKxMlk1KM7:TR?= MXvTRW5ITVJ?
ES4 NULEb4JIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnH[FlKSzVyPUKyN{44QDNizszN MV\TRW5ITVJ?
KARPAS-422 MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TiRWlEPTB;MkK4MlM2OiEQvF2= NVzNeVZMW0GQR1XS
NCI-H1648 M4LObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfETWM2OD1{MkmuOFg6KM7:TR?= NWnWZ2lQW0GQR1XS
ES6 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3ab5NJUUN3ME2yN|kvPDNizszN NEn0RplUSU6JRWK=
KNS-81-FD NFTxbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3tOVBKSzVyPUK0NU4yQTdizszN MWTTRW5ITVJ?
JAR MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPNOJhwUUN3ME2yOVYvOjJ3IN88US=> MXnTRW5ITVJ?
NB1 M3TJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPYTWM2OD1{NkCuOVE3KM7:TR?= MW\TRW5ITVJ?
D-336MG Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrFTWM2OD1{NkCuOlk5KM7:TR?= NV7zR3E2W0GQR1XS
BC-3 NUWySWV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TuNWlEPTB;Mk[1MlE4QCEQvF2= NFXwToRUSU6JRWK=
HCC2218 NFnoXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33Bd2lEPTB;Mk[2MlQyPSEQvF2= NVHLNG81W0GQR1XS
TE-9 NFv6d4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjjd3pVUUN3ME2yOlYvPjJ5IN88US=> MYnTRW5ITVJ?
LB1047-RCC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK3TWM2OD1{Nk[uO|U{KM7:TR?= MUTTRW5ITVJ?
CTB-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHJR2p6UUN3ME2yOlkvQTd|IN88US=> M3\j[XNCVkeHUh?=
NB7 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7RTWM2OD1{N{Gg{txO M33id3NCVkeHUh?=
ST486 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPGNZpHUUN3ME2yO|cvPDF{IN88US=> MVLTRW5ITVJ?
HCC1187 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJ6Mj64NVEh|ryP NF;GbFFUSU6JRWK=
NCI-SNU-16 MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfOfFNKSzVyPUK4OE4zPDhizszN M2DJTnNCVkeHUh?=
COR-L279 MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HjZ2lEPTB;MkmxMlU5PCEQvF2= NF\H[IRUSU6JRWK=
ES8 NWHXbnlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknyTWM2OD1{OUSuNVgzKM7:TR?= NHPVR2lUSU6JRWK=
U-698-M NXfxZoNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDncJhKSzVyPUK5PE4zPDNizszN NUH2WINwW0GQR1XS
HEL Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfSSWxKSzVyPUOwPU4yPDlizszN NHrDXFZUSU6JRWK=
KINGS-1 M1LNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;JXHpKSzVyPUOxNE43PzRizszN NXXrc3QxW0GQR1XS
KY821 M1nhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXjO4hKSzVyPUOzOk42QTVizszN NUj0[YtlW0GQR1XS
MZ1-PC MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnnNphwUUN3ME2zOFUvPjF6IN88US=> NHzwflZUSU6JRWK=
LS-411N NYDxOVd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17wWmlEPTB;M{W0MlY3KM7:TR?= NE\GeHVUSU6JRWK=
SIG-M5 M4rKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fkVGlEPTB;M{W5Mlc5OiEQvF2= MojnV2FPT0WU
HT M{XPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;U[Gc4UUN3ME2zOlcvPzFzIN88US=> MVnTRW5ITVJ?
HC-1 M1XBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P5V2lEPTB;M{[3Mlc5PyEQvF2= MWTTRW5ITVJ?
NCI-H1694 NHf0UlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHyXWZKSzVyPUO3Nk46OzRizszN MXPTRW5ITVJ?
BB65-RCC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:4W3lUUUN3ME2zO|YvOjR3IN88US=> M3LIR3NCVkeHUh?=
HAL-01 M1zHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nCSGlEPTB;M{e5Mlg{QCEQvF2= Ml3iV2FPT0WU
ARH-77 NVzSdnVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj6TWM2OD1|OUSuNFA5KM7:TR?= M1zGZnNCVkeHUh?=
MZ7-mel NX7mRWdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnRUllKSzVyPUO5O{4zOzNizszN MoTLV2FPT0WU
SIMA NIT2O|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO5NXY4UUN3ME20NFMvQTN|IN88US=> MY\TRW5ITVJ?
DG-75 MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC4dpVKSzVyPUSxOU43QThizszN MXHTRW5ITVJ?
HUTU-80 NF\aVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTRzOT6xPFUh|ryP M2nOeHNCVkeHUh?=
KNS-42 MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTR{NT64NVUh|ryP MluyV2FPT0WU
SH-4 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\XXnRwUUN3ME20NlcvPTZ3IN88US=> M{DEUXNCVkeHUh?=
L-540 MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LVbGlEPTB;NEOxMlA{OSEQvF2= Mk\oV2FPT0WU
NB10 M1TTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1naVmlEPTB;NESxMlI{PCEQvF2= NFvze5BUSU6JRWK=
ES1 M{nDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P0PWlEPTB;NEWyMlc2OyEQvF2= MnPaV2FPT0WU
KMOE-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPU[JJKSzVyPUS1Ok44OTFizszN M4i2UXNCVkeHUh?=
MC116 NIHUco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTR3OD6xNVYh|ryP MYjTRW5ITVJ?
RCC10RGB MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULqb|E2UUN3ME20OlAvODB3IN88US=> M{H6UHNCVkeHUh?=
RL95-2 MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3BTlRKSzVyPUS2NE4zOzdizszN M{DJOHNCVkeHUh?=
Raji M4jR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTR4OD6xOFMh|ryP NVrmeWJSW0GQR1XS
CAS-1 NGrNVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHYVVhKSzVyPUS3Nk4xPzNizszN NVvNeVBiW0GQR1XS
Calu-6 M4C4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jRRmlEPTB;NEe1MlI3PSEQvF2= M3vFd3NCVkeHUh?=
KG-1 NUHKOVhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj3Vph2UUN3ME20O|gvPDRizszN NUDyb4tnW0GQR1XS
LB771-HNC NYnOfopQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSxTWM2OD12OEKuNlMzKM7:TR?= NIPYNFRUSU6JRWK=
ACN NYjjbpRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTR7Mz61PVkh|ryP NEHuemxUSU6JRWK=
KM12 NW[0Z5h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTR7Nj61PFkh|ryP MWDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID